Compare ACADIA Pharmaceuticals Inc. (ACAD) vs VanEck Gold Miners ETF (GDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs VanEck Gold Miners ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while VanEck Gold Miners ETF trades at $73.41. The key difference: ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, VanEck Gold Miners ETF nearer its low. Which is the better fit depends on your goals.
| ACAD | GDX | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $115.84 |
52-Week Low | $20.06 | $50.79 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
GDX trades at $78.74, up 0.4% with bearish technical signals from moving averages but neutral oscillators. The ETF faces mixed sentiment as gold miners navigate volatile commodity markets, though some analysts highlight attractive valuations and strong fundamentals. Recent additions like Aya Gold & Silver to the ETF portfolio signal ongoing portfolio optimization.
The outlook remains cautious with technical resistance at $80-$83, while fundamental support comes from record free cash flow yields and discounted multiples. Key risks include gold price volatility and energy cost pressures, but central bank demand and portfolio diversification benefits provide long-term tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About VanEck Gold Miners ETF
The fund normally invests at least 80% of its total assets in common stocks and depositary receipts of companies involved in the gold mining industry. The index is a modified market-capitalization weighted index primarily comprised of publicly traded companies involved in the mining for gold and silver. The fund is non-diversified.
Read more on GDX →
